Treatment with etanercept, a soluble p75/TNFR2 receptor reduces experimental CD pain (16), further corroborating the concept that cytokines, such as TNFα, have a role in immune cell activation during CD, but also as a hyperalgesic function. This evidence concerns the gene TNF and Cowden disease.